Navigation Links
For the Treatment of Rheumatoid Arthritis, Surveyed European Rheumatologists Expect Well-Established TNF-Alpha Inhibitors to Lose Considerable Patient Share to Newer Agents in This Drug Class
Date:10/14/2010

BURLINGTON, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, between 2010 and 2013, surveyed European rheumatologists expect well-established TNF-alpha inhibitors to lose considerable patient share to newer agents in this drug class, most notably Centocor Ortho Biotech/Merck/Mitsubishi Tanabe/Janssen's Simponi and UCB/Otsuka's Cimzia. The increased use of newer agents such as Simponi and Cimzia will most likely occur in newly diagnosed patients and/or in patients who do not respond to initial treatment with a biologic agent.

The new European Physician & Payer Forum report entitled Rheumatoid Arthritis in Europe: How Are Physicians and Payers Responding to an Expanding Arsenal of Biologic Agents? finds that the well-entrenched TNF-alpha inhibitors that stand to lose patient share include Amgen/Pfizer/Takeda's Enbrel, Abbott/Eisai's Humira and Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade. Surveyed European rheumatologists expect a particularly substantial decline by 2013 in the in-class patient share of Remicade -- the only currently marketed intravenous (IV) TNF-alpha inhibitor.

"However, Remicade's lost patient share among TNF-alpha inhibitors will not be fully replaced by uptake of Simponi IV," said Decision Resources Analyst Martin Quinn. "Additionally, considerably more physicians from France, Germany, Spain and the United Kingdom expect to prescribe subcutaneous Simponi than expect to prescribe Simponi IV. This trend will be least pronounced in Italy, where rheumatologists report high patient share for Remicade."

The report findings also suggest that the opportunity to gain patient share is set to increase for recently launched and emerging biologics with alternative mechanisms of action. These agents include Bristol-Myers Squibb's Orencia, Roche/Chugai's RoActemra and Genmab/GlaxoSmithKline's Arzerra. Most notably, surveyed rheumatologists from France, Italy, and Spain predict that at least 40 percent of their patients treated with TNF-alpha inhibitors will receive a subsequent biologic with an alternative mechanism of action by the end of 2013.

The report also finds that patient cost-sharing for rheumatoid arthritis drugs does not pose a significant barrier to treatment for patients in France, Germany, Italy, Spain and the United Kingdom. For example, because patients with severe progressive rheumatoid arthritis in France make no out-of-pocket payments for biologics, private insurers -- most of whom cover only out-of-pocket costs -- do not play a central role in determining access to rheumatoid arthritis drugs.

The report is based on a survey of 250 rheumatologists from Germany (50), France (50), Italy (51), Spain (50) and the United Kingdom (50) and interviews with 16 European payers from Germany (3), France (3), Italy (4), Spain (3) and the United Kingdom (3).

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone
2. Waismann Method Extends Aid in an Effort to Make Treatment More Widely Available
3. FDAs Just Approved Monthly Drug Treatment, Vivitrol Could Be Game Changer, Says Countrys Largest Drug Treatment Recovery President, CRCs Jerry Rhodes; Provides Addicts One Decision A Month Instead of 30
4. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
5. Chongqing Cancer Hospital Becomes First Hospital in Southwest China to Offer Cancer Patients Fast, Precise Treatment Using RapidArc® Radiotherapy from Varian Medical Systems
6. Jazz Pharmaceuticals Receives FDA Complete Response Letter Regarding JZP-6 for Treatment of Fibromyalgia
7. Sunridge Advances its PNT Glaucoma Treatment Throughout China
8. New Report by BioTrends Examines the Treatment of Renal Anemia in China
9. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
10. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
11. Prostate Cancer Treatment Expert Dr. David Samadi, MD Discusses Study Which Found That Low-Income Men Had High-Risk Prostate Cancer Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Aug. 15, 2017   Mostyn Law and Gulf Coast ... Houston, Texas . The Mostyn Law family has ... years. That is why Mostyn Law is partnering with ... to show its appreciation. Blood supplies are running low. ... short of hospital needs in August. That is why the blood ...
(Date:8/14/2017)... Israel , Aug. 15, 2017 /PRNewswire/ ... of adult stem cell technologies for neurodegenerative diseases, announced ... 2017. "We are ... Phase 3 trial to investigate NurOwn ® in ... Executive Officer of BrainStorm. "We have agreements with Mass. ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... Dr. Charles W. Grimsley’s new ... ($15.99, paperback, 9781498497626; $7.99, eBook, 9781498497633) focuses on the treatment of veterans diagnosed ... achieve forgiveness, through a progressive journey toward healing. This book will help readers ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Advice Media, the industry leader in digital marketing ... in North America and has been included in the Inc. 5000 for the second time ... to be included in the Inc. 5000 rankings for the second year in a row. ...
(Date:8/16/2017)... ... August 16, 2017 , ... Summer days spent with family are priceless. ... put together suggestions for enjoying the season of sunshine. Add trying something new to ... family can join in on the fun. , Try Something New ...
(Date:8/16/2017)... ... August 16, 2017 , ... Ten outstanding teachers in the Greater ... Classroom and will win a visit by a Houston Texans player, two tickets to ... least five years old can visit texanschecking.com/stars to nominate their favorite teacher with an ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... In a ... its appearance with diet and exercise. In fact, cellulite can't always be eliminated by ... and more effective treatment available to select physicians nationwide. Dr. Kenneth Rothaus has recently ...
Breaking Medicine News(10 mins):